CoChat

Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease

Miners, James Scott, Barua, Neil, Kehoe, Patrick Gavin, Gill, Steven, Love, Seth · 2011 · Journal of Neuropathology & Experimental Neurology

The DOI matches its Crossref record; 282 of the 287 references it cites were found in a registry or an index.

Abstract

There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes, including neprilysin (NEP), insulin-degrading enzyme, and endothelin-converting enzyme reduce Aβ levels and protect against cognitive impairment in mouse models of AD. The activity of several Aβ-degrading enzymes rises with age and increases still further in AD, perhaps as a physiological response to minimize the buildup of Aβ. The age- and disease-related changes in expression of more recently recognized Aβ-degrading enzymes (e.g. NEP-2 and cathepsin B) remain to be investigated, and there is strong evidence that reduced NEP activity contributes to the development of cerebral amyloid angiopathy. Regardless of the role of Aβ-degrading enzymes in the development of AD, experimental data indicate that increasing the activity of these enzymes (NEP in particular) has therapeutic potential in AD, although targeting their delivery to the brain remains a major challenge. The most promising current approaches include the peripheral administration of agents that enhance the activity of Aβ-degrading enzymes and the direct intracerebral delivery of NEP by convection-enhanced delivery. In the longer term, genetic approaches to increasing the intracerebral expression of NEP or other Aβ-degrading enzymes may offer advantages.

Overview

Integrity signals

Registry

Crossref · 10.1097/nen.0b013e3182345e46

Cites

282 of 282 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

2 retracted

Show all 282 references

Research works printed but not linked: 3

  1. 10.1042/bst0331101 · doi:10.1042/bst0331101 · Paper page
  2. 10.1097/64.5.378 · doi:10.1097/64.5.378
  3. 10.1097/62.9.885 · doi:10.1097/62.9.885

Cited by

See all 277

Metadata

Authors
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S.
Affiliations
Frenchay Hospital (GB)
Corresponding author
Miners, James Scott
Venue
Journal of Neuropathology & Experimental Neurology
Published
2011-11
Volume
70
Issue
11
Pages
944-959
ISSN
  • 0022-3069 (ISSN-L)
  • 1554-6578
OpenAlex
W1994344429
Cited by
265
References
287
Citations by year
2026: 8 · 2025: 7 · 2024: 14 · 2023: 15 · 2022: 14 · 2021: 11 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 23 · 2016: 32 · 2015: 14 · 2014: 31 · 2013: 24 · 2012: 20
FWCI
2.67
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neuropathology & Experimental Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Bristol Research (University of Bristol) (publishedVersion)
Funders
  • James Tudor Foundation
  • Engineering and Physical Sciences Research Council (EP/G061866/1)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
amyloid-beta, Alzheimer's disease, neprilysin, insulin-degrading enzyme, endothelin-converting enzyme, cathepsin B, cerebral amyloid angiopathy, amyloid clearance, convection-enhanced delivery, gene therapy, cognitive impairment
MeSH terms
Alzheimer Disease, Animals, Disease Models, Animal, Glycopeptides, Humans, Insulysin, Mice, Transgenic, Protease Inhibitors, Thiorphan, Neprilysin, Genetic Therapy, Amyloid beta-Peptides, Microglia, Stem Cell Transplantation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease. https://app.cochat.ai/papers/10.1097/nen.0b013e3182345e46
The paper
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011). Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1097/nen.0b013e3182345e46

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.